Avi­ra­gen Ther­a­peu­tics slammed again by its sec­ond tri­al fail­ure in days, this time for their lead drug

In back-to-back set­backs, Avi­ra­gen Ther­a­peu­tics $AVIR says that its lead drug vapen­davir flunked a Phase IIb in mod­er­ate to se­vere asth­mat­ics with a rhi­novirus in­fec­tion.

Nei­ther of the two dos­es in the study – 264 mg or 528 mg – achieved a sta­tis­ti­cal­ly sig­nif­i­cant out­come on the pri­ma­ry end­point.

Just days ago in a Q2 call CEO Joseph Pat­ti called this drug the biotech’s most ad­vanced an­ti-vi­ral.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER